A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease

Trial Profile

A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Lanabecestat (Primary)
  • Indications Alzheimer's disease
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms AMARANTH
  • Sponsors Eli Lilly
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 11 Aug 2016 Planned End Date changed from 1 Aug 2021 to 1 Aug 2019.
    • 08 Apr 2016 According to Astrazeneca media release, the AMARANTH independent data monitoring committee recommended the study continue without modification after a scheduled interim safety analysis was conducted.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top